ORCID as entered in ROS

Select Publications
2025, 'Authors reply: Polymerisation of cyanoacrylates: The effect of sclero-embolic and contrast agents', Phlebology, 40, pp. 55 - 56, http://dx.doi.org/10.1177/02683555241271932
,2024, 'Authors reply: 899 serious adverse events including 13 deaths, 7 strokes, 211 thromboembolic events, and 482 immune reactions: The untold story of cyanoacrylate adhesive closure', Phlebology, 39, pp. 494 - 496, http://dx.doi.org/10.1177/02683555241239553
,2024, '899 serious adverse events including 13 deaths, 7 strokes, 211 thromboembolic events, and 482 immune reactions: The untold story of cyanoacrylate adhesive closure', Phlebology, 39, pp. 80 - 95, http://dx.doi.org/10.1177/02683555231211086
,2024, 'Polymerisation of cyanoacrylates: The effect of sclero-embolic and contrast agents', Phlebology, 39, pp. 114 - 124, http://dx.doi.org/10.1177/02683555231214343
,2021, 'LIPIODOL reduces the lytic activity of detergent sclerosants in vitro', Phlebology, 36, pp. 771 - 778, http://dx.doi.org/10.1177/02683555211018312
,2020, 'Cyanoacrylate closure for peripheral veins: Consensus document of the Australasian College of Phlebology', Phlebology, 35, pp. 153 - 175, http://dx.doi.org/10.1177/0268355519864755
,